Skip to main content
. 2022 Mar 18;14(6):1283. doi: 10.3390/nu14061283

Figure 2.

Figure 2

Beta Diversity of the CAP Start and CAP End phases. (A) C1 Bray–Curtis PCoA Start of Treatment (NS), (B) C1 Bray–Curtis PCoA End of Treatment (p < 0.001), (C) C1 Jaccard Index PCoA Start of Treatment (NS), (D) C1 Jaccard Index PCoA End of Treatment (p < 0.01), (E) C2 Bray–Curtis PCoA Start of Treatment (p < 0.05), (F) C2 Bray–Curtis PCoA End of Treatment (p < 0.05), (G) C2 Jaccard Index PCoA Start of Treatment (p < 0.05), and (H) C2 Jaccard Index PCoA End of Treatment (p < 0.001). Significance was determined using PERMANOVA.